Scanning and combinatorial library services – Save 20% with code TRY-BXPLIB-20

Vmax™ cells

During the past decades, particular interest has been focused on developing effective mucosal vaccines because of their efficiency inducing mucosal and systemic immune responses. However, because of several hurdles, only a handful of mucosal vaccines are commercially available. Orally administered mucosal vaccines pass through host defenses the same way microbial pathogens do; they are diluted in mucosal secretions, degraded by proteases, and subunit vaccines are often not very immunogenic. A promising approach to address low immunogenicity of subunit vaccines is to target the antigen selectively to the receptors in mucosal membranes as an antigen-antibody fusion. Aminopeptidase N (APN) has been identified as the receptor through which some enteric pathogens make their entry. And antibodies against this receptor are known for their internalization across the mucosal surface through this receptor. Here we report the first phase in engineering a novel antigen carrier by fusing a target antigen to an anti-APN antibody.

By clicking View recording, you agree that Codex DNA may use this information to contact you about our programs, products, or services. You may opt out at any time.

Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.

Contact us

The expertise of our scientists, engineers, and supporting teams is always available. Or call us: 858.228.4115

By clicking Submit, you agree that Codex DNA may use this information to contact you about our programs, products, or services. You may opt out at any time.

Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.